Floatz logo

Glofitamab

CYP3A Inhibitor

German Cancer Research CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the CYP3A Inhibitor cohort.

Asset / SponsorPhaseRating
Cobicistat
German Cancer Research Center
Phase 1CC
Obinutuzumab
German Cancer Research Center
Phase 1CC
Eloxatin
German Cancer Research Center
Phase 1CC

Same molecule, other indications

Glofitamab is also rated in:

B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →